JP2023507795A5 - - Google Patents
Info
- Publication number
- JP2023507795A5 JP2023507795A5 JP2022538201A JP2022538201A JP2023507795A5 JP 2023507795 A5 JP2023507795 A5 JP 2023507795A5 JP 2022538201 A JP2022538201 A JP 2022538201A JP 2022538201 A JP2022538201 A JP 2022538201A JP 2023507795 A5 JP2023507795 A5 JP 2023507795A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- approximately
- variable region
- chain variable
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025207453A JP2026048712A (ja) | 2019-12-20 | 2025-11-28 | 第XI/XIa因子抗体の医薬製剤および投薬レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951887P | 2019-12-20 | 2019-12-20 | |
| US62/951,887 | 2019-12-20 | ||
| PCT/US2020/066151 WO2021127525A1 (en) | 2019-12-20 | 2020-12-18 | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207453A Division JP2026048712A (ja) | 2019-12-20 | 2025-11-28 | 第XI/XIa因子抗体の医薬製剤および投薬レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507795A JP2023507795A (ja) | 2023-02-27 |
| JP2023507795A5 true JP2023507795A5 (cg-RX-API-DMAC7.html) | 2023-12-15 |
Family
ID=76478578
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538201A Pending JP2023507795A (ja) | 2019-12-20 | 2020-12-18 | 第XI/XIa因子抗体の医薬製剤および投薬レジメン |
| JP2025207453A Pending JP2026048712A (ja) | 2019-12-20 | 2025-11-28 | 第XI/XIa因子抗体の医薬製剤および投薬レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207453A Pending JP2026048712A (ja) | 2019-12-20 | 2025-11-28 | 第XI/XIa因子抗体の医薬製剤および投薬レジメン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230071973A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4076511A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023507795A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220119090A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115003325A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012064A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3161118A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293367A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021127525A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12703762B2 (en) | 2018-12-18 | 2026-08-11 | Novartis Ag | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
| WO2023092062A1 (en) * | 2021-11-18 | 2023-05-25 | Anthos Therapeutics, Inc. | Dosing regimens of factor xi/xia antibodies |
| EP4461749A4 (en) * | 2022-01-05 | 2025-03-26 | Shanghai Mabgen Biotech Ltd. | Pharmaceutical composition containing anti-FXI/FXIA antibodies and use thereof |
| TW202405022A (zh) * | 2022-06-24 | 2024-02-01 | 美商安瑟斯治療公司 | 與抗因子xi/因子xia抗體之組合療法 |
| DE102022116219A1 (de) * | 2022-06-29 | 2024-01-04 | St. Jude Medical, Cardiology Division, Inc. | Kandidatenscreening für eine Zieltherapie |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200738261A (en) * | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| WO2008039761A2 (en) * | 2006-09-25 | 2008-04-03 | Medimmune, Llc. | Stabilized antibody formulations and uses thereof |
| JP2010531898A (ja) * | 2007-06-28 | 2010-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 鼻および眼へのコルチコステロイド水溶液送達 |
| LT2953969T (lt) * | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| JOP20160131B1 (ar) * | 2015-06-26 | 2022-03-14 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| EP3337517A4 (en) * | 2015-08-20 | 2019-04-17 | Abbvie Stemcentrx LLC | ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE |
| KR102616666B1 (ko) * | 2016-12-23 | 2023-12-27 | 노파르티스 아게 | 인자 xi 항체 및 사용 방법 |
| CN118320078A (zh) * | 2016-12-23 | 2024-07-12 | 诺华股份有限公司 | 采用抗因子XI/XIa抗体治疗的方法 |
| PT3570882T (pt) * | 2017-01-19 | 2022-01-11 | Bayer Pharma AG | Nova formulação estável para anticorpos fxia |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| EP3713965A1 (en) * | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| WO2023092062A1 (en) * | 2021-11-18 | 2023-05-25 | Anthos Therapeutics, Inc. | Dosing regimens of factor xi/xia antibodies |
-
2020
- 2020-12-18 JP JP2022538201A patent/JP2023507795A/ja active Pending
- 2020-12-18 WO PCT/US2020/066151 patent/WO2021127525A1/en not_active Ceased
- 2020-12-18 CN CN202080093971.9A patent/CN115003325A/zh active Pending
- 2020-12-18 US US17/785,660 patent/US20230071973A1/en active Pending
- 2020-12-18 KR KR1020227024670A patent/KR20220119090A/ko active Pending
- 2020-12-18 CA CA3161118A patent/CA3161118A1/en active Pending
- 2020-12-18 IL IL293367A patent/IL293367A/en unknown
- 2020-12-18 EP EP20903182.2A patent/EP4076511A4/en active Pending
- 2020-12-18 BR BR112022012064A patent/BR112022012064A2/pt unknown
-
2025
- 2025-11-28 JP JP2025207453A patent/JP2026048712A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250074985A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| US9220776B2 (en) | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments | |
| JP2021046431A (ja) | 血管性眼疾患を処置するための方法および製剤 | |
| TWI894144B (zh) | 藉由投予il-33拮抗劑治療或預防哮喘之方法 | |
| KR20200034739A (ko) | 고농도 항-c5 항체 제형 | |
| BR112021008778A2 (pt) | Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn | |
| WO2020259605A1 (zh) | 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途 | |
| BR112021010789A2 (pt) | Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar | |
| NO20170737A1 (no) | Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff | |
| JP2026048712A (ja) | 第XI/XIa因子抗体の医薬製剤および投薬レジメン | |
| TW202045537A (zh) | 化膿性汗腺炎的治療 | |
| CN113194821A (zh) | 逆转替卡格雷活性的方法 | |
| TW202128133A (zh) | 重組全人源抗tigit單株抗體製劑及其製備方法和用途 | |
| WO2025130748A1 (zh) | 一种抗凝血因子XI/XIa抗体制剂 | |
| KR20250079929A (ko) | 항-FcRN 항체를 이용한 그레이브스병의 치료 방법 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| RU2745814C1 (ru) | Водная фармацевтическая композиция левилимаба и ее применение | |
| CN116172947A (zh) | 一种含特异性结合vegf和ang2的双特异性抗体的药物组合物 | |
| CN115531531A (zh) | 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途 | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| CN116688115B (zh) | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 | |
| BR112021004900A2 (pt) | anticorpos de quimiocina pan-elr+ cxc para o tratamento de hidradenitis suppurativa | |
| HK40102408B (en) | Pharmaceutical composition containing anti-lag-3 antibody and application thereof | |
| HK40102408A (en) | Pharmaceutical composition containing anti-lag-3 antibody and application thereof | |
| JP2019505516A (ja) | インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法 |